As Global President of Inizio Advisory, Remco op den Kelder leads the Advisory leadership team in facilitating continued growth globally, connecting the organisation’s expertise to drive re
Join our exploration of vital oncology topics, including caring for cancer survivors, AI in patient care, the future of CAR-T therapies, and the rise of targeted radiopharmaceuticals.
The biopharmaceutical industry operates at the intersection of health innovation and market viability, where the significance of integrating market access insights into investment decisions
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.